Minimally Invasive Molecular Staging (MIMS) RT-PCR Breast Cancer Study
Abstract
We have been able to successfully complete the establishment of a 14 institution study group with the enrollment of 550 patients and associated data base. Based on known recurrence rates by our statistical support group predicted That there was enough redundancy in the study to support an appropriate power analysis. As such, the MIMS study the five-year follow up completion with data lock anticipated within the next two months. At the moment, there are 69 outstanding Data Clarification Requests (DCRs) and only 7 patients lost to follow up. To date, our interim analysis has been promising and productive. Overall 18 related publications in peer review journals and two patent applications have resulted directly and/or indirectly from the MIMS project. We anticipate being able to address our primary endpoints, and the majority of the secondary endpoints by the conclusion of the study. Additionally, it is notable that the MIMS study per se has led to the successful establishment of several productive and not independently funded research initiatives which are likely to have a "ripple" effect beyond that of the MIMS trial per se.
Document Details
- Document Type
- Technical Report
- Publication Date
- Mar 31, 2007
- Accession Number
- ADA464655
Entities
People
- David J. Cole
- Megan Baker-ruppel
- Michael Mitas
Organizations
- Medical University of South Carolina